| Document |
Document Title |
|
WO/2024/102417A2 |
|
|
WO/2024/076967A9 |
The present invention provides compositions and methods for reducing the level and/or activity of a TET protein, for treating or preventing a disease and disorder associated with an increased level and/or activity of a TET protein, for r...
|
|
WO/2024/103042A1 |
The present disclosure is related to improved compositions and methods related to viral immunotherapy treatments for cancer. Specifically, provided herein are therapeutic rAAV vectors, particles, and compositions thereof related to treat...
|
|
WO/2024/102666A2 |
The disclosure relates generally to gene editing systems comprising large serine recombinases and methods of using such large serine recombinases for integration of nucleic acid sequences.
|
|
WO/2024/102277A2 |
Compositions and methods for altering flowering and/or maturity time of soybean plant are provided. Compositions include isolated and recombinant polynucleotides encoding polypeptides, expression cassettes, host cells, plants, plant part...
|
|
WO/2024/103060A1 |
This invention is directed to peanut plants or parts thereof comprising at least one mutation in one or more β-ketoacyl-ACP synthetase II (KASII) genes encoding a KasII polypeptide and methods and compositions for making and using the s...
|
|
WO/2024/101755A1 |
The present disclosure relates to a novel method for preparing Taq DNA polymerase, and more specifically, to a method for preparing Taq DNA polymerase in Pichia pastoris, Taq DNA polymerase produced thereby, and a method for amplifying o...
|
|
WO/2024/100292A1 |
The present invention provides a new method that is specifically designed to start statistically from a single copy of a nucleic acid molecule and requires only a single encapsulation step to provide clonal microcompartment libraries dis...
|
|
WO/2024/102943A1 |
Described herein are immunoresponsive cells engineered to express cytokines, chimeric receptors, and synthetic transcription factor systems. Also described herein are nucleic acids, cells, and methods directed to the same.
|
|
WO/2024/102454A1 |
This document relates to methods and materials involved in producing antibodies (e.g., single domain antibody (sdAbs) and/or heavy chain only antibodies) having one or two chimeric heavy chains. For example, (A) genetically engineered no...
|
|
WO/2024/101915A1 |
The present invention relates to a peptide nucleic acid complex having enhanced stability and improved inhibitory effects on a target gene, wherein the terminals of a bioactive peptide nucleic acid and a carrier peptide nucleic acid are ...
|
|
WO/2024/098383A1 |
Disclosed are a protein mutant with a sequence having more than 80% identity to SEQ ID NO. 1, a gRNA used in combination with the protein mutant, a gene editing system, an expression vector, a modified cell, a pharmaceutical composition,...
|
|
WO/2024/100633A1 |
The disclosure describes improved vectors, such as adeno-associated virus (AAV) vectors, for expressing progranulin and variants thereof in transduced cells, and use of such vectors to increase the amount of progranulin in subjects exper...
|
|
WO/2024/099865A1 |
The present invention refers to a cell suspension of autologous adult bone marrow-derived mononuclear cells for use in the treatment or amelioration of a subject suffering or having suffered from an ischemic or a hemorrhagic stroke and m...
|
|
WO/2024/100392A1 |
The present invention provides novel drug-inducible degradation tags (degrons), as well as fusion proteins, cells and pharmaceutical compositions comprising the same. Nucleic acid sequences and vectors encoding the novel degrons are also...
|
|
WO/2024/101063A1 |
Provided is a PHA polymerization enzyme that has high substrate specificity and makes it possible to synthesize a PHA that has a comparatively high molecular weight. A production method for a polyhydroxyalkanoate according to the prese...
|
|
WO/2024/102958A1 |
Provided herein are methods and compositions for processing a target nucleic acid sequence. The methods and compositions provided herein comprise a guide complex for recruiting an enzyme which can introduce a cut on the target nucleic ac...
|
|
WO/2024/098448A1 |
Provided is an embryo culture solution-based non-invasive screening method for preimplantation embryos. Methylation detection is carried out on cell-free DNAs in a culture solution of preimplantation embryos to be detected, and according...
|
|
WO/2024/101357A1 |
An antibody against coatomer protein complex subunit beta 2 (COPB2) or an antigen-binding fragment thereof that contains any of CDR sets (a) to (c): (a) a heavy chain CDR1 comprising an amino acid sequence represented by SEQ ID NO: 1, a ...
|
|
WO/2024/098498A1 |
The present invention relates to an mRNA for encoding an anti-avian influenza H7N9 virus antibody, a preparation method therefor, and use thereof. Specifically, provided is an isolated mRNA composition, which comprises an mRNA comprising...
|
|
WO/2024/098242A1 |
Disclosed are a method for detecting milk production properties of dairy cows using an APOM gene SNPs molecular marker and use. The present invention provides use of a substance for detecting genotypes of the following four SNP sites in ...
|
|
WO/2024/102764A1 |
The disclosure relates to methods of treating cancer in a subject administering nucleic acid molecules comprising a nucleic acid sequence encoding a plurality of neoantigens. Vaccines, compositions comprising coding regions encoding neoa...
|
|
WO/2024/102106A2 |
The present invention relates to a tool and method for targeted downregulation or upregulation of endogenous gene expressions in molecular biology, genetics, stem cell studies, gene therapy and biotechnology applications, developmental b...
|
|
WO/2024/099366A1 |
Disclosed is use of SlPIF4 as a negative regulatory factor in the improvement of melatonin content of tomato fruits. The content of melatonin in the tomato fruits is reduced by means of the overexpression of an SlPIF4 gene driven by a co...
|
|
WO/2024/099089A1 |
Provided are a genetically engineered strain for producing pseudouridine and use thereof in the fermentation and production of pseudouridine. The strain performs heterologous overexpression of a pyrimidine nucleoside operon, overexpressi...
|
|
WO/2024/098148A1 |
There is described herein modified T cells engineered to have decreased IRF2 expression and method of making and using the same for cancer therapy.
|
|
WO/2024/098238A1 |
β-Hemoglobinopathies are hereditary diseases that originate from mutations in the hemoglobin beta (HBB) gene. The general inventive concepts are based on the discovery that hemoglobinopathies can be treated by administration of a dual v...
|
|
WO/2024/102923A1 |
The present disclosure provides a vaccine composition comprising six or more homologous distinct antigen components. Any two of the six or more homologous distinct antigen components may share less than 98% or 95% sequence identity. The ...
|
|
WO/2024/101942A1 |
The present invention relates to cells genetically engineered to express a peptide or a fragment thereof which can inhibit a transforming growth factor-β (TGF-β) signaling pathway.
|
|
WO/2024/101305A1 |
A culture vessel (10) comprises a container body (11) that has an opening (11a) that opens in a slit shape, and that vertically accommodates a sheet-like object (membrane filter (100)) through the opening (11a).
|
|
WO/2024/102942A1 |
Provided are methods for determining that a candidate polypeptide in a library of polypeptides has editing activity comprising expressing in a plurality of cells: a library of first expression cassettes each comprising a nucleic acid enc...
|
|
WO/2024/101385A1 |
Pluripotent stem cells with improved differentiation efficiency are produced while suppressing spontaneous differentiation toward all three germ layers. Pluripotent stem cells are subjected to suspension culture in a liquid medium contai...
|
|
WO/2024/101945A1 |
The present invention relates to a nanoparticle, a nanoparticle complex comprising anti-5'-tRH-GlyGCC bound thereto, and a pharmaceutical composition for preventing or treating cancer comprising same. The present invention may provide an...
|
|
WO/2024/102703A2 |
The disclosure provides for recombinantly modified Zika-based vectors that can be used in gene therapy applications.
|
|
WO/2024/099265A1 |
An engineered immune cell is provided, and in particular, an immune cell modified to co-express a chimeric antigen receptor (CAR) and interleukin-15 (IL-15), a pharmaceutical composition thereof, a use method therefor, and related use th...
|
|
WO/2024/102995A1 |
Disclosed herein, are compositions and methods using Chlamydia Muridarum organisms in the treatment and prevention of human Chlamydia trachomatis infections in a subject. Also, disclosed herein are compositions and methods for eliciting ...
|
|
WO/2024/099163A1 |
Disclosed is use of a Zea mays amino acid transporter and a coding gene thereof in plant disease resistance. Specifically disclosed are a protein having the amino acid sequence of SEQ ID No. 3 and a coding gene thereof. The present inven...
|
|
WO/2024/098353A1 |
Provided is a recombinant Saccharomyces cerevisiae for producing cannabigerolic acid. The recombinant Saccharomyces cerevisiae is prepared from basic Saccharomyces cerevisiae, wherein in the basic Saccharomyces cerevisiae, the following ...
|
|
WO/2024/103051A2 |
Disclosed are exosomes comprising an extracellular HIV gpl20 binding motif. Disclosed are exosomes comprising an extracellular CD4 binding motif. Disclosed are methods of making an engineered mesenchymal stem cell (MSC)-derived exosome c...
|
|
WO/2024/098939A1 |
Provided is a bifunctional fusion protein, comprising a first domain specifically recognizing interleukin-6 receptor (IL-6R), and a second domain specifically binding to cell surface protein CD47. Also provided is a method of using said ...
|
|
WO/2024/101710A1 |
The present invention relates to a pharmaceutical composition for prevention or treatment of glioma, comprising a multiple-epitope peptide, and more specifically to a technique using a multiple-epitope peptide for the use of prevention, ...
|
|
WO/2024/098152A1 |
This disclosure relates to catalytic nucleic acids, catalytic nucleic acid probes, biosensors, lateral flow devices, and kits for detecting the presence or absence of eosinophil peroxidase. Also provided are methods for detecting the pre...
|
|
WO/2024/102867A1 |
Agents, compositions, and methods of minimizing dysregulation of Staufen1-associated RNA metabolism are disclosed and described.
|
|
WO/2024/101303A1 |
An evaluation method of an anticancer agent that includes the following steps in this order: a step of culturing a cell structure containing stromal cells, in which a gene encoding a viable cell marker protein has been knocked out, and c...
|
|
WO/2024/102361A1 |
A pharmaceutical combination includes a beta-lactam antibiotic alone or in combination with a beta-lactamase inhibitor useful for treating multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myel...
|
|
WO/2023/076272A9 |
In certain embodiments, provided are methods for increasing the efficiency of dicot and gymnosperm transformation using BBM with no or minimal plant phenotype. Vector designs for achieving these results are also provided, as are methods ...
|
|
WO/2024/102996A1 |
Systems, methods, and compositions can be used to generate a therapeutic cell. The system can be an fully closed, automated system. The system, methods and compositions can intake cells of a subject and modify the cells to generate thera...
|
|
WO/2024/102965A1 |
Disclosed herein are designer extracellular vesicles (EVs) that target muscle cells. For example, in some embodiments, the EVs are decorated NHERF1, NHERF2, a fusion protein containing an E8 fragment of laminin and an exosomal or lysosom...
|
|
WO/2024/102667A2 |
The disclosure relates to gene editing systems comprising serine recombinases and methods of using such serine recombinases for integration of nucleic acid sequences.
|
|
WO/2024/098116A1 |
The present invention relates to CRISPR/Cas-based biosensing materials, assays and methods. In particular, the technology relates to ultrasensitive CRISPR/Cas-based detection methods for nucleic acid assays using special molecular constr...
|
